Production of active ingredients Olon reports record investments in technology and research and development
Editor: Alexander Stark
In its annual financial statements for 2020, the Italian manufacturer of active ingredients Olon reported record sales as well as investments in technology and research and development.
Companies in this topic
MILAN / ITALY – The manufacturer of active ingredients Olon announces the latest results of the group after the end of 2020: the company confirms its trend in organic growth, the successful integration of several sites acquired in recent years and a historical record for revenue as well as investments in technology and research and development.
The numbers reflect gradual and continuous growth over the past five years. 65 million euros will be allocated to strategic investments during 2021. These investments include, among other things, the expansion of technology platforms and the expansion of production capacities. The Italian group’s strategy focuses on the production of very powerful APIs (active pharmaceutical ingredients).
To support the growth, extensive investments were made at the Rodano (Milan) site, which enabled the plant to significantly increase its production capacity and improve process quality standards as well as environmental compatibility and employee safety. The manufacturer has extensive experience manufacturing highly active ingredients – from the clinical to the commercial scale. In 2021 alone, an investment of €13 million was made into the Rodano site. The API production line has already been completed and up and running.